4D Molecular Therapeutics
FDMT
152 hedge funds and large institutions have $471M invested in 4D Molecular Therapeutics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 49 reducing their positions, and 26 closing their positions.
17% more capital invested
Capital invested by funds: $402M → $471M (+$69.2M)
5.65% more ownership
Funds ownership: 93.51% → 99.16% (+5.6%)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
1% less funds holding
Funds holding: 153 → 152 (-1)
20% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 49
31% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.53M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$11.3M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$5.32M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.51M |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.31M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$15.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.5M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.25M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.57M |
| 5 |
Morgan Stanley
New York
|
-$2.85M |
FDMT Hedge Fund Activity: Q1 2026 in Review
152 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q1 2026, worth a combined $471M — up 17% from $402M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FDMT positions and 26 closed out — a net gain of 2 holders — while 39 added to existing stakes and 49 trimmed.
The largest buyer was Trails Edge Capital Partners, opening a new position worth an estimated $11.3M. The largest seller was BVF Inc, cutting an estimated $15.2M.
- 152 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q1 2026, down from 153 in Q4 2025.
- Funds reported $471M of 4D Molecular Therapeutics stock for Q1 2026, up 17% quarter-over-quarter.
- 28 funds opened new 4D Molecular Therapeutics positions in Q1 2026 and 26 closed out, a net change of +2 holders.
- The largest 4D Molecular Therapeutics buyer in Q1 2026 was Trails Edge Capital Partners, an estimated $11.3M added.
- The largest 4D Molecular Therapeutics seller in Q1 2026 was BVF Inc, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2026.